53.93 USD
+0.19 (+0.35%)
BMRN gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 531 industry peers in the Biotechnology industry. BMRN scores excellent points on both the profitability and health parts. This is a solid base for a good stock. BMRN is valued quite cheap, while showing a decent growth score. This is a good combination! These ratings would make BMRN suitable for value and quality investing!
1. Profitability
1.1 Basic Checks
In the past year BMRN was profitable.
BMRN had a positive operating cash flow in the past year.
BMRN had positive earnings in 4 of the past 5 years.
BMRN had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
BMRN has a Return On Assets of 6.83%. This is amongst the best in the industry. BMRN outperforms 92.47% of its industry peers.
With an excellent Return On Equity value of 8.59%, BMRN belongs to the best of the industry, outperforming 92.09% of the companies in the same industry.
BMRN has a Return On Invested Capital of 7.69%. This is amongst the best in the industry. BMRN outperforms 93.79% of its industry peers.
The Average Return On Invested Capital over the past 3 years for BMRN is significantly below the industry average of 18.22%.
The last Return On Invested Capital (7.69%) for BMRN is above the 3 year average (3.73%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.83% | ||
| ROE | 8.59% | ||
| ROIC | 7.69% |
ROA(3y)3.59%
ROA(5y)4.88%
ROE(3y)4.67%
ROE(5y)6.69%
ROIC(3y)3.73%
ROIC(5y)N/A
1.3 Margins
BMRN has a better Profit Margin (16.82%) than 92.66% of its industry peers.
BMRN has a better Operating Margin (20.21%) than 94.54% of its industry peers.
With an excellent Gross Margin value of 81.32%, BMRN belongs to the best of the industry, outperforming 85.12% of the companies in the same industry.
In the last couple of years the Gross Margin of BMRN has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 20.21% | ||
| PM (TTM) | 16.82% | ||
| GM | 81.32% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.25%
GM growth 5Y0.19%
2. Health
2.1 Basic Checks
BMRN has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
Compared to 1 year ago, BMRN has more shares outstanding
BMRN has more shares outstanding than it did 5 years ago.
BMRN has a better debt/assets ratio than last year.
2.2 Solvency
BMRN has an Altman-Z score of 5.17. This indicates that BMRN is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 5.17, BMRN is in the better half of the industry, outperforming 72.88% of the companies in the same industry.
The Debt to FCF ratio of BMRN is 0.72, which is an excellent value as it means it would take BMRN, only 0.72 years of fcf income to pay off all of its debts.
Looking at the Debt to FCF ratio, with a value of 0.72, BMRN belongs to the top of the industry, outperforming 94.35% of the companies in the same industry.
BMRN has a Debt/Equity ratio of 0.10. This is a healthy value indicating a solid balance between debt and equity.
BMRN's Debt to Equity ratio of 0.10 is on the low side compared to the rest of the industry. BMRN is outperformed by 64.03% of its industry peers.
Although BMRN does not score too well on debt/equity it has very limited outstanding debt, which is well covered by the FCF. We will not put too much weight on the debt/equity number as it may be because of low equity, which could be a consequence of a share buyback program for instance. This needs to be investigated.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.1 | ||
| Debt/FCF | 0.72 | ||
| Altman-Z | 5.17 |
ROIC/WACC0.93
WACC8.28%
2.3 Liquidity
BMRN has a Current Ratio of 4.83. This indicates that BMRN is financially healthy and has no problem in meeting its short term obligations.
BMRN has a Current ratio of 4.83. This is comparable to the rest of the industry: BMRN outperforms 54.05% of its industry peers.
A Quick Ratio of 3.10 indicates that BMRN has no problem at all paying its short term obligations.
BMRN has a worse Quick ratio (3.10) than 61.96% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.83 | ||
| Quick Ratio | 3.1 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 52.00% over the past year.
The Revenue has grown by 12.39% in the past year. This is quite good.
Measured over the past years, BMRN shows a quite strong growth in Revenue. The Revenue has been growing by 10.86% on average per year.
EPS 1Y (TTM)52%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-129.09%
Revenue 1Y (TTM)12.39%
Revenue growth 3Y15.62%
Revenue growth 5Y10.86%
Sales Q2Q%4.08%
3.2 Future
The Earnings Per Share is expected to grow by 27.59% on average over the next years. This is a very strong growth
BMRN is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 7.34% yearly.
EPS Next Y33.85%
EPS Next 2Y44.64%
EPS Next 3Y33.41%
EPS Next 5Y27.59%
Revenue Next Year12.52%
Revenue Next 2Y10.02%
Revenue Next 3Y9.15%
Revenue Next 5Y7.34%
3.3 Evolution
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 20.27, BMRN is valued on the expensive side.
94.16% of the companies in the same industry are more expensive than BMRN, based on the Price/Earnings ratio.
Compared to an average S&P500 Price/Earnings ratio of 26.29, BMRN is valued a bit cheaper.
Based on the Price/Forward Earnings ratio of 11.66, the valuation of BMRN can be described as reasonable.
Based on the Price/Forward Earnings ratio, BMRN is valued cheaper than 97.74% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 23.51, BMRN is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 20.27 | ||
| Fwd PE | 11.66 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, BMRN is valued cheaper than 95.48% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, BMRN is valued cheaper than 97.18% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 12.55 | ||
| EV/EBITDA | 13.01 |
4.3 Compensation for Growth
BMRN's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The decent profitability rating of BMRN may justify a higher PE ratio.
A more expensive valuation may be justified as BMRN's earnings are expected to grow with 33.41% in the coming years.
PEG (NY)0.6
PEG (5Y)N/A
EPS Next 2Y44.64%
EPS Next 3Y33.41%
5. Dividend
5.1 Amount
BMRN does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:BMRN (12/10/2025, 9:31:54 AM)
53.93
+0.19 (+0.35%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners97.86%
Inst Owner Change-1%
Ins Owners0.65%
Ins Owner Change-0.62%
Market Cap10.36B
Revenue(TTM)3.09B
Net Income(TTM)520.42M
Analysts82.35
Price Target92.97 (72.39%)
Short Float %4.69%
Short Ratio3.24
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-48.87%
Min EPS beat(2)-142.18%
Max EPS beat(2)44.44%
EPS beat(4)3
Avg EPS beat(4)-11.96%
Min EPS beat(4)-142.18%
Max EPS beat(4)44.44%
EPS beat(8)6
Avg EPS beat(8)2.48%
EPS beat(12)9
Avg EPS beat(12)14.79%
EPS beat(16)12
Avg EPS beat(16)-9.32%
Revenue beat(2)1
Avg Revenue beat(2)1.98%
Min Revenue beat(2)-2.53%
Max Revenue beat(2)6.48%
Revenue beat(4)2
Avg Revenue beat(4)1.32%
Min Revenue beat(4)-2.53%
Max Revenue beat(4)6.48%
Revenue beat(8)4
Avg Revenue beat(8)1.53%
Revenue beat(12)5
Avg Revenue beat(12)0.37%
Revenue beat(16)7
Avg Revenue beat(16)0.03%
PT rev (1m)-2.86%
PT rev (3m)-5.9%
EPS NQ rev (1m)0%
EPS NQ rev (3m)12.71%
EPS NY rev (1m)-2.6%
EPS NY rev (3m)-15.23%
Revenue NQ rev (1m)0.01%
Revenue NQ rev (3m)1.28%
Revenue NY rev (1m)0.06%
Revenue NY rev (3m)0.06%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 20.27 | ||
| Fwd PE | 11.66 | ||
| P/S | 3.35 | ||
| P/FCF | 12.55 | ||
| P/OCF | 11.34 | ||
| P/B | 1.71 | ||
| P/tB | 1.84 | ||
| EV/EBITDA | 13.01 |
EPS(TTM)2.66
EY4.93%
EPS(NY)4.62
Fwd EY8.57%
FCF(TTM)4.3
FCFY7.97%
OCF(TTM)4.76
OCFY8.82%
SpS16.11
BVpS31.53
TBVpS29.29
PEG (NY)0.6
PEG (5Y)N/A
Graham Number43.44
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.83% | ||
| ROE | 8.59% | ||
| ROCE | 9.17% | ||
| ROIC | 7.69% | ||
| ROICexc | 9.82% | ||
| ROICexgc | 10.68% | ||
| OM | 20.21% | ||
| PM (TTM) | 16.82% | ||
| GM | 81.32% | ||
| FCFM | 26.69% |
ROA(3y)3.59%
ROA(5y)4.88%
ROE(3y)4.67%
ROE(5y)6.69%
ROIC(3y)3.73%
ROIC(5y)N/A
ROICexc(3y)4.34%
ROICexc(5y)N/A
ROICexgc(3y)4.77%
ROICexgc(5y)N/A
ROCE(3y)4.44%
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.25%
GM growth 5Y0.19%
F-Score8
Asset Turnover0.41
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.1 | ||
| Debt/FCF | 0.72 | ||
| Debt/EBITDA | 0.84 | ||
| Cap/Depr | 106.6% | ||
| Cap/Sales | 2.85% | ||
| Interest Coverage | 85.91 | ||
| Cash Conversion | 129.08% | ||
| Profit Quality | 158.68% | ||
| Current Ratio | 4.83 | ||
| Quick Ratio | 3.1 | ||
| Altman-Z | 5.17 |
F-Score8
WACC8.28%
ROIC/WACC0.93
Cap/Depr(3y)111.01%
Cap/Depr(5y)114.82%
Cap/Sales(3y)4.71%
Cap/Sales(5y)5.6%
Profit Quality(3y)57.85%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)52%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-129.09%
EPS Next Y33.85%
EPS Next 2Y44.64%
EPS Next 3Y33.41%
EPS Next 5Y27.59%
Revenue 1Y (TTM)12.39%
Revenue growth 3Y15.62%
Revenue growth 5Y10.86%
Sales Q2Q%4.08%
Revenue Next Year12.52%
Revenue Next 2Y10.02%
Revenue Next 3Y9.15%
Revenue Next 5Y7.34%
EBIT growth 1Y52.68%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year68.31%
EBIT Next 3Y38.69%
EBIT Next 5Y23.21%
FCF growth 1Y2529.91%
FCF growth 3Y36.9%
FCF growth 5YN/A
OCF growth 1Y559.43%
OCF growth 3Y23.45%
OCF growth 5Y63.99%
BIOMARIN PHARMACEUTICAL INC / BMRN FAQ
Can you provide the ChartMill fundamental rating for BIOMARIN PHARMACEUTICAL INC?
ChartMill assigns a fundamental rating of 6 / 10 to BMRN.
Can you provide the valuation status for BIOMARIN PHARMACEUTICAL INC?
ChartMill assigns a valuation rating of 8 / 10 to BIOMARIN PHARMACEUTICAL INC (BMRN). This can be considered as Undervalued.
Can you provide the profitability details for BIOMARIN PHARMACEUTICAL INC?
BIOMARIN PHARMACEUTICAL INC (BMRN) has a profitability rating of 7 / 10.
What is the expected EPS growth for BIOMARIN PHARMACEUTICAL INC (BMRN) stock?
The Earnings per Share (EPS) of BIOMARIN PHARMACEUTICAL INC (BMRN) is expected to grow by 33.85% in the next year.